This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors
This is a Rollover study. Only subjects who continue to receive clinical benefit from
continuation of tinengotinib monotherapy and are tolerating tinengotinib at the time of
enrollment are eligible to participate on this study. Subjects on this rollover study may
continue to receive tinengotinib at the dose that they were previously receiving on the
TransThera parent study and may continue for as long as the subject continues to benefit from
treatment.
Drug: Tinengotinib
Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.
Other Name: TT-00420
Inclusion Criteria:
1. Subject is currently enrolled in a pre-defined TransThera-sponsored parent study and
is receiving tinengotinib as a single agent.
2. Subject is currently deriving clinical benefit from the study treatment, as determined
by the investigator.
Exclusion Criteria:
1. Subject has been permanently discontinued from tinengotinib in the parent protocol for
any reason other than enrollment in the Rollover study
2. Subject does not meet the criteria specified in the parent protocol for continued
treatment on study.
University of Chicago Medical Center
Chicago, Illinois, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
UW Carbone Cancer Center
Madison, Wisconsin, United States
Katie Hennessy, MS
267-627-0150
katie_hennessy@transtherabio.com
Hui Wang, MS
301-859-0848
wang_hui@transtherabio.com
Not Provided